1. Home
  2. SKYE vs EXFY Comparison

SKYE vs EXFY Comparison

Compare SKYE & EXFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

SELL

Current Price

$1.73

Market Cap

9.0M

Sector

Health Care

ML Signal

SELL

Logo Expensify Inc.

EXFY

Expensify Inc.

SELL

Current Price

$2.35

Market Cap

217.0M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
SKYE
EXFY
Founded
2012
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
217.0M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
SKYE
EXFY
Price
$1.73
$2.35
Analyst Decision
Buy
Hold
Analyst Count
4
3
Target Price
★ $68.00
$2.83
AVG Volume (30 Days)
74.3K
★ 512.4K
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $142,101,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$0.15
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 2.06
52 Week Low
$0.26
$0.69
52 Week High
$2.32
$2.81

Technical Indicators

Market Signals
Indicator
SKYE
EXFY
Relative Strength Index (RSI) 53.85 54.29
Support Level $1.57 $2.04
Resistance Level $2.28 $2.41
Average True Range (ATR) 0.20 0.11
MACD -0.06 -0.00
Stochastic Oscillator 31.82 83.59

Price Performance

Historical Comparison
SKYE
EXFY

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.

Share on Social Networks: